Vaccine use recommendations and population-specific considerations described in document excerpts
LAIV (Intranasal) use: LAIV4 (FluMist Quadrivalent) is indicated for persons aged 2 through 49 years; ACIP has at times not recommended LAIV4 in specific seasons because of concerns about low effectiveness (e.g., 2016–17 and 2017–18). LAIV is associated with increased upper respiratory symptoms (runny nose, nasal congestion, sore throat) compared with injected vaccines and has specific contraindications to consider.age 2-49 years; season-specific VE concerns
Follow current ACIP guidance for seasonal use and contraindications.
Inactivated vaccines (IIV): Quadrivalent and trivalent inactivated influenza vaccines are approved for broad age ranges (examples: Fluarix Quadrivalent approved for 6 months and older; Fluzone Quadrivalent approved for 6 months and older). High-dose and adjuvanted formulations (e.g., Fluzone High-Dose, Fluad) are intended for persons aged 65 years and older; ACIP does not express a preference among age-appropriate IIVs, high-dose, adjuvanted, or recombinant vaccines for persons 65+.age-specific approvals (e.g., ≥6 months; ≥65 years)
Use age-appropriate formulation per ACIP.
Recombinant and cell-based vaccines: Recombinant vaccines (e.g., Flublok Quadrivalent) are an egg-free option approved for adults (Flublok Quadrivalent for ≥18 years). Cell culture–based vaccines (Flucelvax Quadrivalent) provide an egg-free alternative and have had age indications expanded (e.g., to ≥2 years per ACIP 2021). These products may be preferred or used for persons with egg allergy as appropriate per ACIP guidance.recombinant ≥18 years; ccIIV4 expanded to ≥2 years
Consider product selection for egg-allergic patients.
Intradermal and dose-sparing approaches: Intradermal administration (e.g., Fluzone Intradermal) was indicated for adults 18 through 64 years and produced more local reactions; the intradermal product was discontinued after the 2017-2018 season. Dose-sparing intradermal strategies showed variable non-inferiority depending on antigen and age subgroup.age 18-64 considerations
Product availability may be limited.
Booster doses in immunocompromised/renal patients: Available evidence (meta-analysis) does not support routine booster influenza doses to enhance immunogenicity in patients on hemodialysis, peritoneal dialysis, or in renal transplant recipients; booster dosing is not recommended for these populations based on current data.population-specific; booster not effective
See pooled sero-protection analyses.
Egg allergy and administration setting: Persons with egg allergy, including those with severe reactions, may receive any licensed, age-appropriate influenza vaccine (IIV4, RIV4, or LAIV4) that is otherwise appropriate for age and health status. If a vaccine other than ccIIV4 or RIV4 is used in persons with a history of severe egg reaction, administer the vaccine in a medical setting with supervision by a provider able to recognize and manage severe allergic reactions. No special postvaccination observation period is specifically required for egg-allergic persons beyond usual practices (consider 15-minute observation to reduce syncope risk).egg allergy severity stratification
Follow ACIP 2021 recommendations for egg allergy management.